Managing Ectopic Pregnancy

---
name: managing-ectopic-pregnancy
language: en
description: Guides ectopic pregnancy evaluation with beta-hCG trending and management algorithms. Use when evaluating ectopic pregnancy, trending beta-hCG, or managing ectopic treatment decisions.
tags:
  - management
  - obstetrics-and-gynecology
  - treatment
  - valuation
metadata:
  author: casemark
  practice_areas:
    - Obstetrics
    - Gynecology
    - Maternal-Fetal Medicine
  document_types:
    - Management Report
  skill_modes:
    - Management
    - Coordination
---

# Managing Ectopic Pregnancy

Guides ectopic pregnancy evaluation with serial β-hCG trending, discriminatory zone application, and evidence-based management algorithms per ACOG Practice Bulletin No. 193.

## Why This Skill Exists

Ectopic pregnancy occurs in approximately 1–2% of all pregnancies and remains a leading cause of first-trimester maternal mortality. Ruptured ectopic pregnancy is a surgical emergency with potential for catastrophic hemorrhage. The critical clinical challenge is distinguishing ectopic from early intrauterine pregnancy (IUP) or pregnancy of unknown location (PUL) using serial β-hCG values and transvaginal ultrasound. The discriminatory zone — the β-hCG level above which an IUP should be visible on TVUS — is central to the diagnostic algorithm.

ACOG Practice Bulletin No. 193 (Tubal Ectopic Pregnancy) establishes the diagnostic criteria, methotrexate eligibility, and surgical indications. Errors in β-hCG interpretation, premature surgical intervention on a desired IUP, or delayed diagnosis of a ruptured ectopic have devastating clinical and medicolegal consequences.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. **Symptoms** — abdominal/pelvic pain (unilateral vs. bilateral), vaginal bleeding, shoulder pain, dizziness, syncope? (Default: from chief complaint)
2. **LMP and estimated gestational age** — how many weeks from LMP? (Default: from history)
3. **Initial β-hCG level** — quantitative serum value and date/time drawn? (Default: from lab results)
4. **Ultrasound findings** — IUP confirmed, adnexal mass, free fluid, empty uterus? (Default: from TVUS report)
5. **Hemodynamic stability** — vital signs, orthostatic symptoms, tachycardia, hypotension? (Default: current vitals)
6. **Risk factors** — prior ectopic, prior tubal surgery, PID history, IUD in situ, IVF pregnancy, smoking? (Default: from history)
7. **Desire for future fertility** — critical for management decision (medical vs. surgical)? (Default: patient preference)
8. **Blood type and Rh status** — RhoGAM needed if Rh-negative? (Default: from prenatal or current labs)

### Documents to Request

- Serial β-hCG values with dates and times
- Transvaginal ultrasound reports (current and prior)
- CBC, type and screen, coagulation studies
- CMP (renal and liver function — required for methotrexate eligibility)
- Prior operative reports (tubal surgery, prior ectopic management)
- Pathology reports (if prior ectopic was treated surgically)

---

## Step 1: Apply the Diagnostic Algorithm

### β-hCG and the Discriminatory Zone

The discriminatory zone is the β-hCG level above which a viable IUP should be visible on TVUS:
- **Discriminatory level: 3,500 IU/L** (institutional range: 1,500–3,500 IU/L)
- Above discriminatory zone + no IUP on TVUS = abnormal pregnancy (ectopic or failed IUP)
- Below discriminatory zone + no IUP = **pregnancy of unknown location (PUL)** → serial β-hCG trending required

### Expected β-hCG Rise in Normal IUP
- Early viable IUP: β-hCG rises by at least **53% in 48 hours** (minimum normal rise, per ACOG)
- The traditional "doubling time of 48 hours" applies to early pregnancies (β-hCG < 10,000)
- Slower rise may still be normal; < 53% rise in 48 hours is abnormal and suggests ectopic or nonviable IUP

### β-hCG Decline Patterns
- After completed miscarriage: β-hCG should decline by ≥ 21–35% in 48 hours
- Slower than expected decline suggests retained products or ectopic
- Plateau (neither rising nor falling adequately) is concerning for ectopic

### Decision Matrix

| Scenario | β-hCG Trend | Ultrasound | Action |
|---|---|---|---|
| Normal IUP | Rising ≥ 53%/48 hrs | IUP confirmed | Routine prenatal care |
| Ectopic confirmed | Any level | Adnexal mass + no IUP; or extrauterine gestational sac with yolk sac/embryo | Manage ectopic (medical or surgical) |
| PUL — likely viable IUP | Rising ≥ 53%/48 hrs | Empty uterus, below discriminatory zone | Repeat β-hCG in 48–72 hrs + TVUS when above discriminatory zone |
| PUL — likely nonviable | Rising < 53%/48 hrs or plateauing | Empty uterus | Ectopic vs. failing IUP; consider D&C with path or serial monitoring |
| PUL — declining | Falling > 50% in 48 hrs | Empty uterus | Likely completed miscarriage; follow to β-hCG < 5 |
| Ruptured ectopic | Any level | Free fluid, hemodynamic instability | **Emergent surgery — do not delay** |

---

## Step 2: Methotrexate (Medical Management)

### Eligibility Criteria for Methotrexate

| Criteria | Requirement |
|---|---|
| Hemodynamic stability | Required — unstable patients → surgery |
| Ectopic mass size | ≤ 3.5 cm (per ACOG; some extend to 4 cm) |
| No fetal cardiac activity on US | Required (cardiac activity = relative contraindication, higher failure rate) |
| β-hCG level | < 5,000 IU/L ideal; success rate drops above 5,000 |
| Patient ability to follow up | Must be able to return for serial β-hCG monitoring |
| Renal function | Normal creatinine |
| Hepatic function | Normal transaminases |
| WBC count | > 1,500/μL |
| Platelet count | > 100,000/μL |
| No immunodeficiency | — |
| No breastfeeding | Methotrexate is contraindicated in breastfeeding |

### Methotrexate Protocols

| Protocol | Dosing | Monitoring |
|---|---|---|
| **Single-dose** | MTX 50 mg/m² IM (day 1) | β-hCG days 4 and 7; if < 15% decline between days 4–7, give second dose |
| **Two-dose** | MTX 50 mg/m² IM days 1 and 4 | β-hCG days 4 and 7; if < 15% decline between days 4–7, give doses on days 7 and 11 |
| **Multi-dose** | MTX 1 mg/kg IM on days 1, 3, 5, 7 alternating with leucovorin 0.1 mg/kg on days 2, 4, 6, 8 | β-hCG before each MTX dose; stop when 15% decline achieved |

Post-methotrexate monitoring:
- Weekly β-hCG until < 5 IU/L
- Avoid NSAIDs, folate supplements, alcohol, and intercourse until resolved
- Warn about transient β-hCG rise between days 1–4 (expected, not treatment failure)
- Watch for treatment failure signs: increasing pain, hemodynamic change, rising β-hCG after day 7

---

## Step 3: Surgical Management

### Indications for Surgery
- Hemodynamic instability (ruptured ectopic)
- Contraindication to methotrexate
- Failed methotrexate (rising β-hCG after day 7 of second dose)
- Patient preference
- Fetal cardiac activity on ultrasound
- β-hCG > 5,000 IU/L (higher failure rate with medical management)

### Surgical Options

| Procedure | Description | Fertility Considerations |
|---|---|---|
| **Salpingostomy** | Linear incision over ectopic, removal of products, tube preserved | Preferred if contralateral tube is damaged or absent |
| **Salpingectomy** | Complete removal of affected tube | Preferred if contralateral tube is healthy; lower recurrence risk |

Post-surgical:
- Follow β-hCG weekly to < 5 IU/L (persistent ectopic tissue requires retreatment in 5–20% of salpingostomy cases)
- RhoGAM if Rh-negative (50 mcg if < 12 weeks, 300 mcg if ≥ 12 weeks)
- Pathology confirmation of ectopic tissue

---

## Step 4: Special Situations

### Heterotopic Pregnancy
- Coexisting IUP + ectopic; incidence is 1:30,000 naturally but up to 1:100 with ART
- Methotrexate is **contraindicated** (would harm the IUP)
- Treatment: surgical removal of ectopic with preservation of IUP

### Interstitial (Cornual) Ectopic
- Located in intramural portion of the tube
- Higher rupture risk with more severe hemorrhage
- May present later (up to 12–16 weeks) due to myometrial distensibility
- Surgical: cornual resection or cornuostomy; consider uterine artery embolization

### Cesarean Scar Ectopic
- Implantation within the cesarean scar niche
- Increasing incidence with rising cesarean rates
- Management: methotrexate, uterine artery embolization, hysteroscopic resection, or laparotomy

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. **Is the β-hCG trend documented** with at least two values, dates, and calculated % change?
2. **Is the discriminatory zone applied correctly** — and does the action match the scenario?
3. **Are methotrexate eligibility criteria checked** before recommending medical management?
4. **Is Rh status addressed** with RhoGAM administered or planned if Rh-negative?
5. **Is the follow-up plan explicit** — serial β-hCG schedule, return precautions, and failure criteria?

---

## Quality Audit

- [ ] Quantitative β-hCG documented with date, time, and serial values
- [ ] β-hCG trend calculated (% rise or decline in 48 hours)
- [ ] Discriminatory zone defined (institutional threshold stated)
- [ ] TVUS findings documented (IUP present/absent, adnexal mass, free fluid)
- [ ] Hemodynamic status documented
- [ ] Risk factors for ectopic documented
- [ ] Methotrexate eligibility criteria systematically checked (all elements)
- [ ] Methotrexate protocol specified (single-dose, two-dose, or multi-dose) with dosing
- [ ] Post-methotrexate monitoring schedule documented
- [ ] Surgical indication documented (if operative management chosen)
- [ ] Procedure type documented (salpingostomy vs. salpingectomy) with rationale
- [ ] Rh status documented and RhoGAM administered/planned
- [ ] Pathology confirmation of ectopic tissue documented (surgical cases)
- [ ] Patient counseled on ectopic precautions (pain, bleeding, return to ED)
- [ ] β-hCG follow-up schedule documented until < 5 IU/L

---

## Guidelines

1. **Never diagnose ectopic based on a single β-hCG** — serial values and ultrasound findings are required for diagnosis (unless ultrasound shows definitive extrauterine pregnancy with cardiac activity).
2. **The discriminatory zone is a guideline, not an absolute** — multiple gestations and early IUPs may not be visible at the traditional threshold; use caution before intervening on a desired pregnancy.
3. **A rising β-hCG does not exclude ectopic** — ectopic pregnancies can show normal-appearing rises in up to 21% of cases.
4. **Methotrexate is not risk-free** — it requires reliable patient follow-up; do not administer if the patient cannot return for serial monitoring.
5. **Ruptured ectopic is a surgical emergency** — hemodynamic instability with a positive pregnancy test and free fluid mandates immediate operative intervention without waiting for β-hCG trends.
6. **Salpingectomy is preferred when the contralateral tube is healthy** — it eliminates the risk of persistent ectopic and recurrence in the same tube.
7. **Follow β-hCG to zero after ANY ectopic management** — persistent trophoblastic tissue occurs in 5–20% of salpingostomy cases and requires surveillance.
8. **Always give RhoGAM to Rh-negative patients** — ectopic pregnancy is a sensitizing event.